Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27

Molecular Endocrinology

Volumn 15, Issue 5, 2001, Pages 765-782

  Waltregny, David ^a   Leav, Irwin ^c   Signoretti, Sabina ^a,b   Soung, Peggy ^a   Lin, Douglas ^a   Merk, Frederick ^c   Adams, Jason Y ^c   Bhattacharya, Nandita ^a   Cirenei, Nicola ^a   Loda, Massimo ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE; FLUTAMIDE; PROTEIN P27; TESTOSTERONE PROPIONATE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CASTRATION; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; EPITHELIUM CELL; HORMONAL REGULATION; IMMUNOHISTOCHEMISTRY; INTRON; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 17744375952     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.15.5.0640     Document Type: Article

References (78)

1. The endocrinology and developmental biology of the prostate
2. Cell proliferation studies in the rat prostate. I. The proliferative role of basal and secretory cells during normal growth
3. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement
4. Androgen regulation of programmed death of normal and malignant prostatic cells
5. Hormonal effects on cell proliferation in rat prostate
6. Androgen receptor levels and androgen contents in the prostate lobes of intact and testosterone-treated Noble rats
7. Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats
8. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats
9. Androgen repression of cytokeratin gene expression during rat prostate differentiation: Evidence for an epithelial stem cell-associated marker
10. Cellular response to androgen depletion and repletion in the rat ventral prostate: Autoradiography and morphometric analysis
11. Gene activity during the early phase of androgen-stimulated rat prostate regrowth
12. Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma
13. Cyclin-dependent kinases: Engines, clocks, and microprocessors
14. Cancer cell cycles
15. Cell cycle checkpoints: Preventing an identity crisis
16. Cell cycle and cancer: Critical events at the G1 restriction point
17. CDK inhibitors: Positive and negative regulators of G1-phase progression
18. Inhibitors of the Cip/Kip family
19. p27 a cyclin- Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest
20. Cloning of p27, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
21. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
22. Dependence of cyclin E-CDK2 kinase activity on cell anchorage
23. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27) of cyclin-dependent kinase 4 activation
24. Growth inhibitory effect of interferon-β is associated with the induction of cyclin-dependent kinase inhibitor p27 in a hyman gastric carcinoma cell line
25. The role of p27 in γ-interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells
26. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/KIP1
27. Interleukin-2-mediated elimination of the p27 cyclin-dependent kinase inhibitor prevented by rapamycin
28. Requirement of p27 for restriction point control of the fibroblast cell cycle
29. Abrogation of p27 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts
30. Cyclin E-CDK2 is a regulator of p27
31. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation
32. Cell-free degradation of p27(kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome
33. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27
34. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
35. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27
36. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
37. AFX-Iike Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27
38. Critical role for p27 in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3)
39. Distinct altered patterns of p27 gene expression in benign prostatic hyperplasia and prostatic carcinoma
40. Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest
41. Translational control of p27 accumulation during the cell cycle
42. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice
43. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1)
44. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors
45. The absence of p27, an inhibitor of G1 cyclin-dependent kinases, uncouples differentiation and growth arrest during the granulosa-luteal transition
46. Hormone-induced proliferation and differentiation of granulosa cells: A coordinated balance of the cell cycle regulators cyclin D2 and p27
47. Oligodendrocyte precursor differentiation is perturbed in the absence of the cyclin-dependent kinase inhibitor p27
48. The cell cycle regulator p27 contributes to growth and differentiation of osteoblasts
49. Multiple functions of p27(Kip1) and its alterations in tumor cells: A review
50. Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells
51. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention
52. Prostate stem cell compartments: Expression of the cell cycle inhibitor p27 in normal, hyperplastic, and neoplastic cells
53. Involvement of p27 in G1 arrest by high dose 5 α-dihydrotestosterone in LNCaP human prostate cancer cells
54. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27 in androgen-induced cell cycle arrest
55. Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence
56. Isolation and characterization of mouse probasin: An androgen-regulated protein specifically expressed in the differentiated prostate
57. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
58. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation
59. In vivo ubiquitination and proteasome-mediated degradation of p53
60. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins
61. Proteosome-dependent regulation of p21/CIP1 expression
62. Biochemical characterization of prostatic nuclei. II. Relationship between DNA synthesis and protein synthesis
63. Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction
64. Cell proliferation studies in the rat prostate. II. The effects of castration and androgen-induced regeneration upon basal and secretory cell proliferation
65. Loss of the cyclin-dependent kinase inhibitor p27(kip1) protein in human prostate cancer correlates with tumor grade
66. Accumulation of the p27/KIP1 cyclin-dependent kinase inhibitor and the timing of oligodendrocyte differentiation
67. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27
68. The cyclin dependent kinase inhibitor p27 safeguards against inflammatory injury
69. p27 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells
70. Molecular cloning and characterization of the human p27 gene promoter
71. skp2 promotes p27 degradation and induces S phase in quiescent cells
72. The F-box protein skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: Evidence for a role of cul1 in the suppression of skp2 expression in quiescent fibroblasts
73. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase
74. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter
75. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma
76. Real-time quantitative RT-PCR after laser-assisted cell picking
77. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases
78. p63 is a prostate basal cell marker and is required for prostate development